Press time:2021-07-12From:CR Pharma [ Font:BigMediumSmall]
On July 12, China Resources Biopharmaceutical Co., Ltd. (hereafter referred to as CR Biopharmaceutical) and Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (hereafter referred to as Biocytogen) reached comprehensive strategic cooperation. According to the agreement, the two parties will develop new drugs for multiple targets selected by both parties in the field of oncology and immunology indications; the two parties also reached a framework cooperation agreement on the methods of cooperation as well as clinical and commercialization issues.
With the innovative RenMab platform, the RenMice HiTS (Hyperimmune Target Specific) Platform, and the integrated antibody drug development platform, Biocytogen will provide CR Biopharmaceutical with support for early drug discovery and development as well as a basis for cooperation between the two parties. CR Biopharmaceutical boasts the advantage of a complete industry chain, which is conducive to the success of drug development and the introduction of drugs to the market.
Based on the consensus on the development strategy in the biopharmaceutical market, the two parties hope that in the future, they will give full play to their respective advantages in technology platforms, drug R&D and the complete industry chain, and further expand their cooperation in the development of full human antibodies and related drugs, thus promoting the development of China in the field of innovative biopharmaceuticals. Both parties are committed to satisfying the clinical needs of major related diseases and jointly contributing to the well-being of the people in China and around the world.
